7 results
Search Results
2. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.
- Author
-
Dar, A., Schajnovitz, A., Lapid, K., Kalinkovich, A., Itkin, T., Ludin, A., Kao, W.-M., Battista, M., Tesio, M., Kollet, O., Cohen, N. N., Margalit, R., Buss, E. C., Baleux, F., Oishi, S., Fujii, N., Larochelle, A., Dunbar, C. E., Broxmeyer, H. E., and Frenette, P. S.
- Subjects
CHEMOKINES ,LEUCOCYTES ,STEM cell transplantation ,HEMATOPOIETIC stem cells ,POLYSACCHARIDES ,NORADRENALINE ,CELL receptors ,ANIMAL experimentation ,BIOTHERAPY ,BONE marrow ,CELL culture ,COMPARATIVE studies ,CONNECTIVE tissue cells ,CYTOKINES ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,MICE ,RESEARCH ,EVALUATION research ,PHARMACODYNAMICS ,CELL physiology - Abstract
Steady-state egress of hematopoietic progenitor cells can be rapidly amplified by mobilizing agents such as AMD3100, the mechanism, however, is poorly understood. We report that AMD3100 increased the homeostatic release of the chemokine stromal cell derived factor-1 (SDF-1) to the circulation in mice and non-human primates. Neutralizing antibodies against CXCR4 or SDF-1 inhibited both steady state and AMD3100-induced SDF-1 release and reduced egress of murine progenitor cells over mature leukocytes. Intra-bone injection of biotinylated SDF-1 also enhanced release of this chemokine and murine progenitor cell mobilization. AMD3100 directly induced SDF-1 release from CXCR4(+) human bone marrow osteoblasts and endothelial cells and activated uPA in a CXCR4/JNK-dependent manner. Additionally, ROS inhibition reduced AMD3100-induced SDF-1 release, activation of circulating uPA and mobilization of progenitor cells. Norepinephrine treatment, mimicking acute stress, rapidly increased SDF-1 release and progenitor cell mobilization, whereas β2-adrenergic antagonist inhibited both steady state and AMD3100-induced SDF-1 release and progenitor cell mobilization in mice. In conclusion, this study reveals that SDF-1 release from bone marrow stromal cells to the circulation emerges as a pivotal mechanism essential for steady-state egress and rapid mobilization of hematopoietic progenitor cells, but not mature leukocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
3. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex.
- Author
-
Ratajczak, M. Z., Lee, H., Wysoczynski, M., Wan, W., Marlicz, W., Laughlin, M. J., Kucia, M., Janowska-Wieczorek, A., and Ratajczak, J.
- Subjects
STEM cells ,BONE marrow ,BLOOD cells ,ERYTHROCYTES ,BLOOD ,HEMATOPOIETIC stem cells ,ERYTHROCYTE metabolism ,ANIMAL experimentation ,BIOTHERAPY ,CELL receptors ,CELL motility ,COMPLEMENT (Immunology) ,CYTOKINES ,ENZYME-linked immunosorbent assay ,GLYCOLS ,HEAT ,HETEROCYCLIC compounds ,IMMUNITY ,MICE ,PHOSPHOLIPIDS ,RESEARCH funding ,ANTI-HIV agents ,COLONY-forming units assay ,PHARMACODYNAMICS ,PHYSIOLOGY - Abstract
The complement cascade (CC) becomes activated and its cleavage fragments play a crucial role in the mobilization of hematopoietic stem/progenitor cells (HSPCs). Here, we sought to determine which major chemoattractant present in peripheral blood (PB) is responsible for the egress of HSPCs from the bone marrow (BM). We noticed that normal and mobilized plasma strongly chemoattracts HSPCs in a stromal-derived factor-1 (SDF-1)-independent manner because (i) plasma SDF-1 level does not correlate with mobilization efficiency; (ii) the chemotactic plasma gradient is not affected in the presence of AMD3100 and (iii) it is resistant to denaturation by heat. Surprisingly, the observed loss of plasma chemotactic activity after charcoal stripping suggested the involvement of bioactive lipids and we focused on sphingosine-1-phosphate (S1P), a known chemoattracant of HSPCs. We found that S1P (i) creates in plasma a continuously present gradient for BM-residing HSPCs; (ii) is at physiologically relevant concentrations a chemoattractant several magnitudes stronger than SDF-1 and (iii) its plasma level increases during mobilization due to CC activation and interaction of the membrane attack complex (MAC) with erythrocytes that are a major reservoir of S1P. We conclude and propose a new paradigm that S1P is a crucial chemoattractant for BM-residing HSPCs and that CC through MAC induces the release of S1P from erythrocytes for optimal egress/mobilization of HSPCs. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
4. Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes.
- Author
-
Lee, H. M., Wu, W., Wysoczynski, M., Liu, R., Zuba-Surma, E. K., Kucia, M., Ratajczak, J., and Ratajczak, M. Z.
- Subjects
BONE marrow ,GRANULOCYTES ,LABORATORY mice ,IMMUNITY ,CYTOKINES ,ANIMAL experimentation ,BIOTHERAPY ,CELL physiology ,COMPLEMENT (Immunology) ,GRANULOCYTE-colony stimulating factor ,GLUCANS ,HEMATOPOIETIC stem cells ,MICE ,PEPTIDES ,RESEARCH funding - Abstract
We reported that complement cascade (CC) becomes activated in bone marrow (BM) during granulocyte colony-stimulating factor (G-CSF) mobilization of hematopoietic stem/progenitor cells (HSPCs) and showed that, although third CC component (C3)-deficient mice are easy mobilizers, fifth CC component (C5)-deficient mice mobilize very poorly. To explain this, we postulated that activation/cleavage of CC releases C3a and C5a anaphylatoxins that differently regulate mobilization. Accordingly, C3a, by enhancing responsiveness of HSPCs to decreasing concentrations of stromal-derived growth factor-1 (SDF-1) in BM, prevents mobilization and promotes their BM retention. Therefore, in this study, we focused on the mobilization-enhancing role of C5a. We found that C5a receptor (C5aR) is not expressed on the surface of HSPCs, and that C5a-mediated promobilization effects are mediated by stimulation of granulocytes. Overall, our data support the following model. First C5aR(+) granulocytes are chemoattracted by plasma C5 cleavage fragments, being the first wave of cells leaving BM. This facilitates a subsequent egress of HSPCs. In the next step, after leaving BM, granulocytes undergo degranulation in response to plasma C5a and secrete some cationic peptides (cathelicidin, beta-defensin) that, as shown here for the first time, highly enhance the responsiveness of HSPCs to plasma SDF-1 gradient. In conclusion, our data reveal the underappreciated central role of innate immunity in mobilization, in which C5 cleavage fragments through granulocytes orchestrate this process. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
5. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
- Author
-
Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Kumar, S., Munshi, N. C., Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. San, Ludwig, H., Hajek, R., Jagannath, S., Blade, J., Lonial, S., Dimopoulos, M. A., Einsele, H., and Barlogie, B.
- Subjects
MULTIPLE myeloma ,DRUG therapy ,HEMAPHERESIS ,STEM cell transplantation ,THERAPEUTICS ,MULTIPLE myeloma diagnosis ,MULTIPLE myeloma treatment ,AUTOGRAFTS ,BIOTHERAPY ,HEMATOPOIETIC stem cell transplantation ,HETEROCYCLIC compounds ,ANTI-HIV agents - Abstract
Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
6. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft.
- Author
-
Pelus, L. M. and Fukuda, S.
- Subjects
CHEMOKINES ,HEMATOPOIETIC stem cells ,APOPTOSIS ,LEUKEMIA ,BONE marrow cells ,BIOTHERAPY ,CELL receptors ,CYTOKINES ,GRANULOCYTE-colony stimulating factor ,HEMATOPOIETIC stem cell transplantation ,IMMUNOPHENOTYPING ,MICE ,STEM cells ,IMMUNOCOMPROMISED patients ,CELL physiology - Abstract
Stem cell research is currently focused on totipotent stem cells and their therapeutic potential, however adult stem cells, while restricted to differentiation within their tissue or origin, also have therapeutic utility. Transplantation with bone marrow hematopoietic stem cells (HSC) has been used for curative therapy for decades. More recently, alternative sources of HSC, particularly those induced to exit marrow or mobilize to peripheral blood by G-CSF, have become the most widely used hematopoietic graft and show significant superiority to marrow HSC. The chemokine/chemokine receptor axis also mobilizes HSC that occurs more rapidly than with G-CSF. In mice, the HSC and progenitor cells (HPC) mobilized by the CXCR2 receptor agonist GRObeta can be harvested within minutes of administration and show significantly lower levels of apoptosis, enhanced homing to marrow, expression of more activated integrin receptors and superior repopulation kinetics and more competitive engraftment than the equivalent cells mobilized by G-CSF. These characteristics suggest that chemokine axis-mobilized HSC represent a population of adult stem cells distinct from those mobilized by G-CSF, with superior therapeutic potential. It remains to be determined if the chemokine mobilization axis can be harnessed to mobilize other populations of unique adult stem cells with clinical utility. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
7. Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide.
- Author
-
Menéndez, P, Prósper, F, Bueno, C, Arbona, C, San Miguel, J F, García-Conde, J, Solá, C, Hornedo, J, Cortés-Funes, H, and Orfao, A
- Subjects
STEM cells ,FLOW cytometry ,BREAST cancer ,ANTIGENS ,BIOTHERAPY ,BREAST tumors ,COMPARATIVE studies ,GRANULOCYTE-colony stimulating factor ,HEMATOPOIETIC growth factors ,IMMUNOPHENOTYPING ,LEUKAPHERESIS ,RESEARCH methodology ,MEDICAL cooperation ,RECOMBINANT proteins ,RESEARCH ,EVALUATION research ,CYCLOPHOSPHAMIDE - Abstract
Administration of stem cell factor (SCF) has been proven to enhance cytokine-induced mobilization of CD34+ hematopoietic progenitor cells (HPC) into the peripheral blood (PB). The aim of the present study was to explore in a homogeneous group of 22 uniformly treated breast cancer patients: (1) the kinetics of mobilization into PB of both CD34+ and CD34- cell subsets, including dendritic cells, in sequential samples obtained from day +7 up to day +12 after mobilization; and (2) the composition of the CD34+ and CD34- cell subsets present in the two leukapheresis products obtained for each patient. The following CD34+ and CD34- subsets were analyzed: early CD34+ HPC, erythroid-, myeloid- and B-lymphoid-committed CD34+ precursor cells, mature T, B and NK cells, monocytes, neutrophils, eosinophils, basophils, and dendritic cells (DC) including three subsets of lin-/HLADR+DC (CD16+, CD33high and CD123high). Our results show that the absolute number of PB CD34+ HPC progressively increases from day +7 onwards. As far as the CD34- PB leukocyte subsets are concerned, monocytes (CD14+) displayed the earliest recovery after mobilization predicting neutrophil recovery 1 day in advance. The number of CD34+ HPC collected in a single leukapheresis product was always > or = 1.4 x 10(6) cells/kg body weight. No significant changes were observed between the two leukapheresis sessions either as regards their composition in CD34+ HPC subsets or their CD34- leukocyte populations except for a higher ratio of both CD34+ erythroid/CD34+ myeloid HPC (0.35 +/- 0.13 vs 0.30 +/- 0.13; P = 0.04) and neutrophils/monocytes (1.58 +/- 2.1 vs 0.69 +/- 0.27; P = 0.009) found for the first leukapheresis. Interestingly, the overall number of dendritic cells (DC) was higher in the second leukapheresis (1.06 +/- 0.56 vs 1.9 +/- 0.46; P = 0.02) due to a selective increase of the CD16+ antigen-presenting cells. In summary, our results show that the combination of cyclophosphamide, G-CSF and SCF is highly effective for stem cell mobilization, with differences observed in the mobilization kinetics of the different hematopoietic cell subsets analyzed. [ABSTRACT FROM AUTHOR]
- Published
- 2001
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.